Medicare payment for physician-administered (Part B) drugs Paul B. Ginsburg and Steven M. Lieberman Wednesday, February 10, 2021
Understanding the No Surprises Act Loren Adler, Matthew Fiedler, Paul B. Ginsburg, Mark Hall, Benedic Ippolito, and Erin Trish Thursday, February 4, 2021
Balancing lower U.S. prescription drug prices and innovation – Part 2 Steven M. Lieberman, Paul B. Ginsburg, and Kavita Patel Wednesday, November 25, 2020
Balancing lower U.S. prescription drug prices and innovation – Part 1 Steven M. Lieberman, Paul B. Ginsburg, and Kavita Patel Tuesday, November 24, 2020
Sharing drug rebates with Medicare Part D patients: Why and how Steven M. Lieberman, Paul B. Ginsburg, and Erin Trish Monday, September 14, 2020
Understanding the bipartisan Senate Finance prescription drug reform package Loren Adler, Paul B. Ginsburg, and Steven M. Lieberman Thursday, October 3, 2019
Considerations for expanding international reference pricing beyond Medicare Part B Loren Adler, Steven M. Lieberman, Christen Linke Young, and Paul B. Ginsburg Monday, September 9, 2019
The use of vendors in Medicare Part B drug payment Paul B. Ginsburg, Caitlin Brandt, and Steven M. Lieberman Friday, August 2, 2019
Rep. Ruiz’s arbitration proposal for surprise billing (H.R. 3502) would lead to much higher costs and deficits Loren Adler, Erin Duffy, Paul B. Ginsburg, Mark Hall, Erin Trish, and Christen Linke Young Tuesday, July 16, 2019
CMS’s International Pricing model for Medicare Part B drugs: Implementation issues Steven M. Lieberman and Paul B. Ginsburg Tuesday, July 9, 2019
